Genentech

FibroGen Inc is a biopharmaceutical company based in South San Francisco, CA, specializing in the development of innovative therapies for serious and life-threatening diseases. With a focus on pancreatic cancer, prostate cancer, Duchenne muscular dystrophy, and anemia, the company is dedicated to bringing about positive changes in patients' lives through its pipeline of novel products. Driven by a commitment to responsible development, FibroGen Inc is actively engaged in clinical trials and collaborates with partners to accelerate the introduction of world-class innovations, particularly in China. With a growing team of dedicated professionals, the company strives to foster a culture of innovation and make a global impact in the field of biopharmaceuticals.Generated from the website

Nabi Biopharmaceuticals develops and markets products that fight serious medical conditions. The company focuses on developing products that address commercial opportunities. Its main business areas encompass Gram-positive bacterial infections, hepatitis, kidney disease and nicotine addiction. Nabi Biopharmaceuticals product brands include PhosLo, Nabi-HB and Aloprim along with a number of products in various stages of clinical and pre-clinical development. Nabi Biopharmaceuticals maintains its international headquarters in Boca Raton, Fla., with principal research and development offices and laboratories in Rockville, Md. The company's European headquarters, Nabi Biopharmaceuticals Europe Limited, is located in Bray, Ireland.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The company has collaborated with pharmaceutical partners to develop and market product candidates. Rigel has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia, asthma and allergy, as well as in cancer. Its lead product candidate, R788, completed Phase I clinical trials for the treatment of rheumatoid arthritis, in 2005.